Literature DB >> 6194125

The immunomodulatory action of inosiplex in relation to its effects in experimental viral infections.

H Ohnishi, H Kosuzume, H Inaba, M Ohkura, S Shimada, Y Suzuki.   

Abstract

The effect of inosiplex (Isoprinosine) on viral replication, experimental viral infections and host immune functions has been examined. Inosiplex was found to have a broad spectrum of antiviral activity, inhibiting the RNA viruses, influenza (INFV) and parainfluenza (PIV), as well as the DNA viruses, herpes simplex (HSV) and vaccinia (VACV). However, the antiviral effects were modest when compared to amantadine and adenine arabinoside (ARA-A). Inosiplex in vivo caused a statistically significant increase in survival of treated animals (hamster, mice) infected with RNA or DNA viruses. This effect of inosiplex was apparent in animals which were previously immunosuppressed. Inosiplex, at optimal dose, conferred total protection in treated mice against secondary influenza infection. Since this was accompanied by statistically significant increases in serum anti-hemagglutinin and anti-neuraminidase titers, an effect of inosiplex on host defenses against secondary viral infection was implicated. This effect was further demonstrated by passive transfer of protection by splenocytes from inosiplex-treated donors to untreated recipients. Inosiplex was found to enhance the mitogen- (PHA-, ConA and MLC-) induced blastogenesis of lymphocytes from untreated mice. The LPS response was not affected. Inosiplex added in vitro caused a dose-dependent increase in the primary immune anti-SRBC response in vitro, as determined by direct and indirect PFC; there was also a dose-dependent effect on the secondary in vitro direct and indirect PFC responses. Inosiplex in vivo enhanced the primary immune response to SRBC, as determined by direct PFC assay; this was also the case for immunosuppressed mice. The drug enhanced delayed type hypersensitivity to picryl chloride in the mouse. Macrophage function was also enhanced by inosiplex, as was apparent from phagocytosis of SRBC. Gamma interferon production from murine lymphocytes was augmented by inosiplex in vitro. Treatment with inosiplex had no effect on natural killer cells or on antibody dependent cellular cytotoxicity. Thus, the pronounced effect of inosiplex on secondary viral infections may result through two different mechanisms: a direct antiviral effect and an elevation of multiple parameters of host immunity, which are usually compromised during viral infection. The latter mechanism may be the more important.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6194125     DOI: 10.1016/0192-0561(83)90055-3

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  7 in total

1.  Combinations of isoprinosine and 3'-azido-3'-deoxythymidine in lymphocytes infected with human immunodeficiency virus type 1.

Authors:  R F Schinazi; D L Cannon; B H Arnold; D Martino-Saltzman
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

2.  Protective effect of isoprinosine in genetically susceptible BALB/c mice infected with Leishmania major.

Authors:  E Cillari; M Dieli; P Lo Campo; G Sireci; A Caffarelli; E Maltese; S Millott; S Milano; F Y Liew
Journal:  Immunology       Date:  1991-09       Impact factor: 7.397

3.  Subacute sclerosing panencephalitis : diagnosis and drug treatment options.

Authors:  B Anlar
Journal:  CNS Drugs       Date:  1997-02       Impact factor: 5.749

Review 4.  Inosine pranobex. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  D M Campoli-Richards; E M Sorkin; R C Heel
Journal:  Drugs       Date:  1986-11       Impact factor: 9.546

Review 5.  A Review on Inosine Pranobex Immunotherapy for Cervical HPV-Positive Patients.

Authors:  Stefan Miladinov Kovachev
Journal:  Infect Drug Resist       Date:  2021-06-02       Impact factor: 4.003

Review 6.  Inosine Pranobex: A Key Player in the Game Against a Wide Range of Viral Infections and Non-Infectious Diseases.

Authors:  Jiri Sliva; Chrysoula N Pantzartzi; Martin Votava
Journal:  Adv Ther       Date:  2019-06-05       Impact factor: 3.845

7.  Genotoxicity and Mutagenicity of Inosine Pranobex.

Authors:  Sylwia Tobólska; Sylwia Terpiłowska; Jerzy Jaroszewski; Andrzej Krzysztof Siwicki
Journal:  J Vet Res       Date:  2018-10-24       Impact factor: 1.744

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.